Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 55-59

  Tórsdóttir, Gudlaug ^a,b   Gudmundsson, Grétar ^c   Kristinsson, Jakob ^a   Snaedal, Jón ^b   Jóhannesson, Torkell ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b Department of Geriatrics ^*  (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Ceruloplasmin; Heterozygotes; SOD1; Wilson disease

Indexed keywords

CERULOPLASMIN; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHROMOSOME 13; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; ENZYME ACTIVITY; ENZYME ANALYSIS; ERYTHROCYTE; EXON; FEMALE; GENE DELETION; GENE MUTATION; HETEROZYGOTE; HUMAN; ICELAND; MALE; OXIDATION; WILSON DISEASE;

EID: 70449713431     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s4360     Document Type: Article

References (22)

1. Ferenci P. Pathophysiology and clinical features of Wilson's disease. Metab Brain Dis. 2004;19:229-239. (Pubitemid 39361185)
2. Bull CP, Gordon TR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5:327-337. (Pubitemid 23351302)
3. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993;5:344-350. (Pubitemid 23351304)
4. Cox DW, Clarke Fraser F, Sass-Kortsak A. A genetic study of Wilson's disease: Evidence for heterogeneity. Amer J Hum Genet. 1972;24:646-666.
5. Asonuma K, InomataY, Kasahara M, et al. Living related liver transplantation from heterozygote genetic carriers to children with Wilson's disease. Pediatr Transplant. 1999;3:201-205. (Pubitemid 29399939)
6. Marklund SL, Ek B, Steen L. Effect of long-term penicillinamine therapy on erythrocyte CuZn superoxide dismutase activity. Scand J Clin Lab Invest. 1984;44:13-17. (Pubitemid 14171498)
7. Alexander NM, Benson GD. Superoxide dismutase activity (erythrocuprein) in Wilson's disease. Life Sci. 1975;16:1025-1032.
8. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172:367-379. (Pubitemid 40208726)
9. Thomas GR, Jensson Ó, Gudmundsson G, Thorsteinsson L, Cox DW. Wilson's disease in Iceland: A clinical and genetic study. Am J Hum Genet. 1995;56:1140-1146.
10. Boyett JD, Lehmann HP, Beeler MF. Automated assay of ceruloplasmin by kinetic analysis of o-dianisidine oxidation. Acta Clin Chem. 1976;69:233-241.
11. Nebot C, Moutet P, Huet P, Xu JZ, Yadan JC, Chaudiere J. Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of tetracyclic cathechol. Anal Biochem. 1993;214:442-451. (Pubitemid 23336403)
12. Gibbs K, Walshe JM. A study of the Caeruloplasmin concentration found in 75 patients with Wilson's disease, their kinship and various control groups. Quart J Med. 1979;191:447-463. (Pubitemid 10200361)
13. Gollan JL, Stocks J, Dormandy TL, Sherlock S. Reduced oxidase activity in the ceruloplasmin of two families with Wilson's disease. J Clin Path. 1977;30:81-83. (Pubitemid 8066385)
14. Quinn NP, Marsden CD. Coincidence of Wilson's disease with other movement disorders in the same family. J Neurol Neurosurg Psychiatry. 1986;49:221-222.
15. Barbosa ER, Kostow UP, Hirsch R, Cancado ER, Scaff M, Canelas HM. Association of Wilson's disease with non-Wilsonian extrapyramidal syndrome in the same family (abstract). Arq Neuropsiquiatr. 1990;48:501-504. (Article in Portuguese).
16. Nicholl DJ, Ferenci P, Polli C, Burdon MB, Pall HS. Wilson disease presenting in a family with an apparent dominant history of tremor. J Neurol Neurosurg Psychiatry. 2001;70:514-516. (Pubitemid 32269690)
17. Kuhn J, Miyajima H, Takahashi Y, et al. Extrapyramidal and cerebellar movement disorder in association with heterozygous ceruloplasmin gene mutation. J Neurol. 2005;252:111-113. (Pubitemid 40179030)
18. Snaedal J, Kristinsson J, Gunnarsdóttir S, Ólafsdó ttir Á, Baldvinsson M, Jóhannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. Dementia. 1998;9:239-242. (Pubitemid 28377223)
19. Tórsdóttir G, Kristinsson J, Sveinbjörnsdóttir S, Snaedal J, Jóhannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol. 1999;85:239-243.
20. Tórsdóttir G, Kristinsson J, Sveinbjörnsdóttir S, Snaedal J, Jóhannesson T. Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: A follow up study. J Neurol Sci. 2006;241:53-58. (Pubitemid 43112516)
21. Kasapoglu M, Ozben T. Alterations of antioxidant enzymes and oxidative stress markers in aging. Exp Gerontol. 2001;36:209-220. (Pubitemid 32164433)
22. Musci G, Bonaccorsi di Patti MC, Fagiolo U, Calabrese L. Age-related changes in human ceruloplasmin. Evidence for oxidative modifications. J Biol Chem. 1993;268:13388-13395. (Pubitemid 23307763)